FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the pharmaceutical industry and includes a polycyclic derivative of carbamoyl pyridone, presented below, or a stereoisomer, or a pharmaceutically acceptable salt thereof, an application thereof, a pharmaceutical composition and a method for treatment based thereon.
EFFECT: polycyclic derivative of carbamoyl pyridone, exhibiting inhibitory effect against 5'-cap-dependent endonuclease.
12 cl, 6 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG FOR INFLUENZA TREATMENT, CHARACTERIZED BY THE FACT THAT IT COMBINES A PER-DEPENDENT ENDONUCLEASE INHIBITOR AND A DRUG AGAINST FLU | 2016 |
|
RU2745071C2 |
SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | 2016 |
|
RU2712275C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | 2017 |
|
RU2727962C1 |
ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | 2008 |
|
RU2493160C2 |
DERIVATIVE OF PYRIDOPYRIMIDINE, METHOD FOR PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE | 2019 |
|
RU2778524C2 |
BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
DEUTERATED DERIVATIVES OF 2-(IMIDAZOLE-4-YL)-ETHANAMIDE PENTANEDIOIC-1,5 ACID | 2021 |
|
RU2783866C2 |
HETEROCYCLIC COMPOUNDS AS TRK INHIBITORS | 2019 |
|
RU2803817C2 |
CD73 INHIBITOR, ITS PRODUCTION METHOD AND ITS USE | 2020 |
|
RU2787428C1 |
Authors
Dates
2022-04-14—Published
2019-04-11—Filed